← Back to Clinical Trials
Recruiting NCT05361122

Prevention of Developmental Delay and Xylitol (PDDaX) Study

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Prematurity
Sponsor University of Washington
Study Type INTERVENTIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 4 Years
Max Age 8 Years
Start Date 2023-04-04
Completion 2027-08-31
Interventions
Maternal Use of Xylitol Chewing Gum During PregnancyNo Maternal Xylitol Chewing Gum Use During Pregnancy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goals of this study are to: evaluate and validate the low-cost, transportable, easily-administered Malawi Developmental Assessment Tool (MDAT) for neurodevelopmental assessment of children aged 4-8 years old in Malawi, as compared to the gold-standard yet more cumbersome and costly Kaufman Assessment Battery for Children-II (KABC-II) among (1) n=500 formerly preterm children and (2) n=500 formerly term children. Additionally, we will evaluate the effects of gestational xylitol exposure compared to a lack of gestational xylitol exposure on neurodevelopmental outcomes of children aged 4-8 years old in Malawi through the following four neurodevelopmental tests: (3) KABC-II (cognitive outcomes), (4) EF Touch (executive functions), (5) Strengths and Difficulties Questionnaire (social-emotional outcomes), and (6) MDAT (motor and cognitive outcomes). The researchers will leverage subjects who completed the parent Prevention of Prematurity and Xylitol Trial, which enrolled 10069 pregnant individuals in Malawi and demonstrated a significant 24% reduction in incidence of preterm birth and low birthweight offspring in gravidae who chewed xylitol-containing chewing gum compared to those who did not. By ensuring that these offspring did not have higher rates of neurodevelopmental impairment, the study will promote promising multi-center international and domestic trial evaluating the impact of xylitol-containing chewing gum use and optimal dosage during pregnancy.

Eligibility Criteria

Inclusion Criteria: * Child born during the PPaX trial * Enrollment age between 4-8 years old * Parental or legal guardian consent obtained * Willing to undergo 3 neurodevelopmental tests * Willing to travel to BCMF for neurodevelopmental assessment * Assent by the pediatric subject for participation in the study Exclusion Criteria: * Parent or legal guardian cognitively unable to provide consent * Child unwilling to provide assent to participate in the study

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}